Wang Danher, Hevey Michael, Juompan Laure Y, Trubey Charles M, Raja Nicholas U, Deitz Stephen B, Woraratanadharm Jan, Luo Min, Yu Hong, Swain Benjamin M, Moore Kevin M, Dong John Y
Division of Bio-defense Vaccines, GenPhar Inc., 871 Lowcountry Blvd., Mount Pleasant, SC 29464, USA.
Virology. 2006 Sep 30;353(2):324-32. doi: 10.1016/j.virol.2006.05.033. Epub 2006 Jul 3.
The Marburg virus (MARV), an African filovirus closely related to the Ebola virus, causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, treatment of disease is only supportive, and no vaccines are available to prevent spread of MARV infections. In order to address this need, we have developed and characterized a novel recombinant vaccine that utilizes a single complex adenovirus-vectored vaccine (cAdVax) to overexpress a MARV glycoprotein (GP) fusion protein derived from the Musoke and Ci67 strains of MARV. Vaccination with the cAdVaxM(fus) vaccine led to efficient production of MARV-specific antibodies in both mice and guinea pigs. Significantly, guinea pigs vaccinated with at least 5 x 10(7) pfu of cAdVaxM(fus) vaccine were 100% protected against lethal challenges by the Musoke, Ci67 and Ravn strains of MARV, making it a vaccine with trivalent protective efficacy. Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine candidate to prevent and contain multi-strain infections by MARV.
马尔堡病毒（MARV）是一种与埃博拉病毒密切相关的非洲丝状病毒，可导致人类致命性出血热，死亡率高达90%。目前，该疾病的治疗仅为支持性治疗，尚无疫苗可用于预防MARV感染的传播。为满足这一需求，我们研发并鉴定了一种新型重组疫苗，该疫苗利用单一复合腺病毒载体疫苗（cAdVax）来过量表达源自MARV的穆索凯株和Ci67株的MARV糖蛋白（GP）融合蛋白。用cAdVaxM(fus)疫苗进行接种可在小鼠和豚鼠体内有效产生MARV特异性抗体。值得注意的是，用至少5×10⁷ pfu的cAdVaxM(fus)疫苗接种的豚鼠对MARV的穆索凯株、Ci67株和拉夫恩株的致死性攻击具有100%的保护作用，使其成为一种具有三价保护效力的疫苗。因此，cAdVaxM(fus)疫苗是预防和控制MARV多株感染的一种有前景的候选疫苗。
